Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
NCT ID: NCT04519944
Last Updated: 2023-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
666 participants
OBSERVATIONAL
2020-06-30
2023-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
NCT02944019
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
NCT03718559
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
NCT05540587
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
NCT01059682
Study of DU-176b Aged 80 Years or Older
NCT02801669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NVAF patients undergoing PCI
Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
Edoxaban
This is an observational, prospective study; no treatment will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Edoxaban
This is an observational, prospective study; no treatment will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Providing written informed consent (ICF) for participation in the study
* NVAF treated with edoxaban
* Successful PCI
* No planned elective cardiac intervention for the whole duration of the study (up to 1 year)
* Capability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
* Availability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
* Willingness of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
* Not simultaneously participating in any interventional study
* Life expectancy \> 1 year
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo Deutschland GmbH
UNKNOWN
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Leader
Role: STUDY_DIRECTOR
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zentralklinik Bad Berka
Bad Berka, , Germany
SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald
Bad Friedrichshall, , Germany
Kerckhoff-Klinik GmbH
Bad Nauheim, , Germany
Herz- und Diabeteszentrum Nordrhein-Westfalen
Bad Oeynhausen, , Germany
Schüchtermann-Schiller'sche Kliniken Bad Rothenfelde GmbH & Co. KG
Bad Rothenfelde, , Germany
Charité - Campus Mitte
Berlin, , Germany
Charité - Campus Benjamin Franklin
Berlin, , Germany
Deutsches Herzzentrum Berlin
Berlin, , Germany
GFO-Kliniken, Standort St.-Marienhospital Bonn
Bonn, , Germany
StädtischesKlinikum Brandenburg
Brandenburg, , Germany
Klinikum Braunschweig
Braunschweig, , Germany
Klinikum Chemnitz
Chemnitz, , Germany
REGIOMED-KLINIKEN GmbH, Klinikum Coburg
Coburg, , Germany
Krankenhaus der Augustinerinnen Köln
Cologne, , Germany
St. Vinzenz-Hospital Köln
Cologne, , Germany
Universitätsklinikum Köln
Cologne, , Germany
Evangelisches Krankenhaus Kalk gGmbH
Cologne, , Germany
Kreiskrankenhaus Demmin GmbH
Demmin, , Germany
Klinikum Lippe Detmold
Detmold, , Germany
St. Johannes-Hospital Dortmund
Dortmund, , Germany
Herzzentrum Dresden GmbH Universitätsklinik an der Technischen Universität Dresden
Dresden, , Germany
Krankenhaus Eggenfelden
Eggenfelden, , Germany
Universitätsklinikum Essen
Essen, , Germany
CCB Cardioangiologisches Centrum Bethanien
Frankfurt, , Germany
Klinikum Frankfurt Höchst GmbH
Frankfurt am Main, , Germany
Universitäts Herzzentrum Freiburg Bad Krozingen
Freiburg im Breisgau, , Germany
Klinikum Fürth
Fürth, , Germany
SRH Wald-Klinikum Gera
Gera, , Germany
Universitätsklinikum Greifswald
Greifswald, , Germany
Klinikum Gütersloh
Gütersloh, , Germany
Asklepios Klinik St. Georg
Hamburg, , Germany
Asklepios Kliniken Hamburg GmbH - Aklepios Klinik Barmbek
Hamburg, , Germany
Asklepios Klinikum Harburg
Harburg, , Germany
SLK-Kliniken Heilbronn
Heilbronn, , Germany
Klinikum Nordfriesland
Husum, , Germany
Universitätsklinikum Jena
Jena, , Germany
SRH Klinikum Karlsbad-Langensteinbach GmbH
Karlsbad, , Germany
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Kiel, , Germany
Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin
Koblenz, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, , Germany
UKSH Lübeck
Lübeck, , Germany
Klinikum Lüdenscheid, Märkische Gesundheitsholding GmbH & Co. KG
Lüdenscheid, , Germany
Carl-von-Basedow-Klinik Saalekreis GmbH
Merseburg, , Germany
Technische Universität München, Klinikum rechts der Isar
München, , Germany
München Klinik gGmbH, Klinik Neuperlach
München, , Germany
St. Franziskus-Hospital GmbH
Münster, , Germany
Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Kardiologie
Oldenburg, , Germany
St. Vincenz Krankenhaus
Paderborn, , Germany
Harzklinikum Dorothea Christiane Erxleben GmbH
Quedlinburg, , Germany
Universitätsmedizin Rostock
Rostock, , Germany
Herz-Kreislauf-Zentrum Rotenburg
Rotenburg an der Fulda, , Germany
Leopoldina
Schweinfurt, , Germany
Klinikum Westmünsterland GmbH
Stadtlohn, , Germany
Robert-Bosch-Krankenhaus GmbH
Stuttgart, , Germany
SRH Zentralklinikum Suhl, Innere Medizin I
Suhl, , Germany
Krankenhaus der Barmherzigen Brüder Trier
Trier, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Herzzentrum Saar
Völklingen, , Germany
Kliniken Nordoberpfalz AG
Weiden, , Germany
GRN-Klinik Weinheim
Weinheim, , Germany
Klinikum Wilhelmshaven gGmbH
Wilhelmshaven, , Germany
Petrus-Krankenhaus Wuppertal
Wuppertal, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Heinrich-Braun-Klinikum Zwickau
Zwickau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baldus S, Beyer-Westendorf J, Mollmann H, Rottbauer W, Beyerlein E, Goette A. Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design. Sci Rep. 2023 Oct 25;13(1):18215. doi: 10.1038/s41598-023-44345-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DS-EDO-01-20-DE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.